Semler Scientific (OTC: SMLR) reported Q1 EPS of $0.33, $0.05 better than the analyst estimate of $0.28. Revenue for the quarter came in at $9.43 million versus the consensus estimate of $9.38 million.

For the quarter ended March 31, 2020, compared to the quarter ended March 31, 2019, Semler Scientific reported:

• Revenues of $9,430,000, an increase of $2,669,000, or 39%, compared to $6,761,000
• Cost of revenues of $850,000, a decrease of $46,000, or 5%, compared to $896,000. As a percentage of revenues, cost of revenues was 9%, compared to 13%
• Total operating expenses, which includes cost of revenues, of $5,978,000, an increase of $1,071,000, or 22%, compared to $4,907,000
• Pre-tax net income of $3,450,000, an increase of $1,596,000, or 86%, compared to $1,854,000
• Net income of $2,673,000, or $0.41 per basic share and $0.33 per diluted share, an increase of $819,000, or 44%, compared to $1,854,000, or $0.29 per basic share and $0.23 per diluted share. As a percentage of revenues, net income was 28% compared to 27%
• Cash of $11,214,000, an increase of $6,670,000, compared to $4,544,000

"In these uncertain and turbulent times driven by the COVID-19 pandemic, acute care for patients is of paramount importance," said Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific. "When we return to a semblance of normalcy, there may be much catching up to do on prevention for chronic diseases."

For earnings history and earnings-related data on Semler Scientific (SMLR) click here.